Sign In
Buy CPRX
$31.28
+0.0100 (+0.0320%)
At Close: Jun 03, 2026
Why Is Catalyst (CPRX) Down 12.6% Since Last Earnings Report?
01:16pm, Wednesday, 08'th Sep 2021
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Catalyst Pharmaceuticals Appoints Mary Coleman as Vice President, Head of Investor Relations
08:03am, Monday, 16'th Aug 2021
CORAL GABLES, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, d
Catalyst (CPRX) Up More Than 20% in Past 3 Months: Here's Why
02:04pm, Wednesday, 11'th Aug 2021
Catalyst's (CPRX) lead drug, Firdapse, is approved for treating Lambert-Eaton myasthenic syndrome. The drug has seen solid uptake since its launch.
Catalyst (CPRX) Q2 Earnings Top Estimates, Revenues Rise Y/Y
05:03pm, Tuesday, 10'th Aug 2021
Catalyst's (CPRX) earnings and revenues beat estimates in the second quarter of 2021. Shares inch up in after-hours trading.
Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q2 2021 Results - Earnings Call Transcript
03:02pm, Tuesday, 10'th Aug 2021
Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q2 2021 Results - Earnings Call Transcript
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Top Estimates
07:59pm, Monday, 09'th Aug 2021
Catalyst (CPRX) delivered earnings and revenue surprises of 77.78% and 16.37%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update
04:39pm, Monday, 09'th Aug 2021
-Q2 2021 Total Net Revenues of $36.4 Million Reflect Strong Quarter over Quarter Growth
Catalyst Pharmaceutical (CPRX) Reports Next Week: What Awaits?
04:45pm, Monday, 02'nd Aug 2021
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CORAL GABLES, Fla., July 26, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, d
Do Earnings Reports Matter for Biotech Stocks?
06:19am, Saturday, 24'th Jul 2021
Yes, but it often doesn't have much to do with revenue.
Catalyst Pharmaceuticals Announces Issuance of U.S. Patent 11,060,128 a Method of Use Patent with Claims Covering Firdapse®
08:03am, Monday, 19'th Jul 2021
CORAL GABLES, Fla., July 19, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licens
Catalyst (CPRX) Thrives on Firdapse But Overdependence Concerns
11:35am, Thursday, 15'th Jul 2021
Catalyst's (CPRX) Firdapse is approved for treating Lambert-Eaton myasthenic syndrome. The drug has seen solid uptake since its launch.
Catalyst Pharmaceuticals Expands Leadership Team with Appointment of Preethi Sundaram, Ph.D. as Chief Product Development Officer
08:03am, Tuesday, 06'th Jul 2021
CORAL GABLES, Fla., July 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,
Catalyst Pharmaceuticals Appoints Pharmaceutical Executive Molly Harper to its Board of Directors
08:03am, Tuesday, 29'th Jun 2021
CORAL GABLES, Fla., June 29, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,
Catalyst Pharmaceuticals Comments on Recent Decision by Health Canada to Re-issue an NOC for Ruzurgi®
04:30pm, Monday, 28'th Jun 2021
CORAL GABLES, Fla., June 28, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,
